USA Archives

News and Trends 16 Aug 2022

Programmable medicines company Senda Biosciences closes $123M series C financing

U.S.-headquartered Senda Biosciences, Inc. has completed $123 million in series C financing, bringing its total funding raised to date to $266 million. Flagship Pioneering, which founded Senda, participated along with new investors, including the Samsung Life Science Fund, Qatar Investment Authority (QIA), Bluwave Capital, and Stage 1 Ventures. Also participating in the financing are current […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech company working on a new investigational class of engineered circular RNA (oRNA) therapies, are to collaborate on discovering, developing, and commercializing multiple programs, including vaccines and therapeutics, in the areas of infectious diseases and oncology. Under the terms of the […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

ADC Therapeutics announces $175M loan from Owl Rock

News and Trends 16 Aug 2022

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

ADC Therapeutics has announced a series of major strategic transactions involving hundreds of millions of dollars allowing it to advance its lead candidate and pipeline drugs. The Swiss company has entered into a new $175 million senior secured loan with certain funds of Owl Rock – a division of Blue Owl Capital, Inc. and funds […]

August 16, 2022 - 3 minutesmins - By Liza Laws

PBC clinical trials: Gannex doses first patient

News and Trends 16 Aug 2022

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […]

August 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Aug 2022

Genentech lymphoma treatment gets FDA approval

Genentech, a part of the Roche Group, says the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy. Polivy (polatuzumab vedotin-piiq), in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). The FDA […]

August 16, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Remedium raises more funds for osteoarthritis gene therapy candidate

Remedium Bio, Inc., a biotech company developing novel gene therapies, has closed more than $2.3 million in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss. The study is being undertaken in a collaboration with Tufts University […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Aptinyx fibromyalgia drug misses endpoint

Biopharma company Aptinyx Inc. says its phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia did not achieve statistically significant separation from placebo on the study’s primary endpoint. “We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients, in this follow-up phase […]

August 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Aug 2022

Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva

On this week’s podcast, we have conversations with ARCH Venture Partners’ managing director Kristina Burow; founder and CEO of Micropep Thomas Laurent; Kylie O’Keefe, SVP, commercial & corporate strategy at PTC Therapeutics, and Juan Carlos Jaramillo, chief medical officer of Valneva. ARCH Venture Partners closes $2.97B biotech fund ARCH Venture Partners has announced the closing […]

August 12, 2022

conveyor belt of medical vials for scale up production

News and Trends 11 Aug 2022

Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors

Regen BioPharma, Inc. has filed with the United States Patent and Trademark Office a provisional U.S. patent application covering the company’s novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion.” CAR-T cells are effective at treating certain lymphomas and leukemias with […]

August 11, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Aug 2022

First patient enrolled on Panbela’s trial for treatment of pancreatic cancer

Panbela Therapeutics, a U.S.-based clinical stage company, announced today (August 11) that it has enrolled its first patient in a global trial to evaluate a potential cure for pancreatic cancer. The trial referred to as ASPIRE will involve studying SBP-101, a treatment for metastatic pancreatic ductal adenocarcinoma. It is a randomized, double-blind placebo-controlled, trial with […]

August 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Aug 2022

Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout

Synlogic, Inc. has announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks. The new candidate, SYNB2081, is a synthetic biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential […]

August 11, 2022 - 2 minutesmins - By Jim Cornall

beta-thalassemia blood APS antiphospholipid syndrome

News and Trends 11 Aug 2022

Study of drug to treat porphyria disorders initiated by Disc Medicine

A phase 2 clinical study of bitopertin in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) has been initiated by Disc Medicine. The announcement of the study, called BEACON, was made August 10. EPP or XLP belong to a group of the porphyria disorders, which are all characterized by abnormally high levels of chemicals, […]

August 11, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Programmable medicines company Senda Biosciences closes $123M series C financing

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

Genentech lymphoma treatment gets FDA approval

Remedium raises more funds for osteoarthritis gene therapy candidate

Aptinyx fibromyalgia drug misses endpoint

Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva

Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors

First patient enrolled on Panbela’s trial for treatment of pancreatic cancer

Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout

Study of drug to treat porphyria disorders initiated by Disc Medicine

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!